{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:39:13Z","timestamp":1791517153205,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bjid.2023.102759","type":"journal-article","created":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T14:41:58Z","timestamp":1679755318000},"page":"102759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015\u20122020"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-1851","authenticated-orcid":false,"given":"Mark G.","family":"Wise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elkin V.","family":"Lemos-Luengas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael R.","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2023.102759_bib0001","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jac\/dkz456","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-2017)","volume":"75","author":"Spiliopoulou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2023.102759_bib0002","doi-asserted-by":"crossref","first-page":"e01814","DOI":"10.1128\/AAC.01814-18","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM global surveillance program, 2012 to 2015","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2023.102759_bib0003","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/jac\/dkaa089","article-title":"In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017","volume":"75","author":"Stone","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2023.102759_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2021.101647","article-title":"In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017\u20122019","volume":"25","author":"Karlowsky","year":"2021","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.bjid.2023.102759_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-0711-11-29","article-title":"Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010","volume":"11","author":"Fern\u00e1ndez-Canigia","year":"2012","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.bjid.2023.102759_bib0006","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/dkaa504","article-title":"Aztreonam\/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia, and Latin America in 2019","volume":"76","author":"Sader","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2023.102759_bib0007","first-page":"672","article-title":"The in vitro activity of ceftazidime-avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in S\u00e3o Paulo, Brazil","volume":"17","author":"Rossi","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.bjid.2023.102759_bib0008","unstructured":"World Health Organization. 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"10.1016\/j.bjid.2023.102759_bib0009","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2019. Available at: www.cdc.gov\/DrugResistance\/Biggest-Threats.html."},{"key":"10.1016\/j.bjid.2023.102759_bib0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.bjid.2023.102759_bib0011","series-title":"Methods For Dilution Antimicrobial Susceptibility Tests For Bacteria that Grow Aerobically: Eleventh Edition: Approved Standard M07-A11","year":"2018"},{"key":"10.1016\/j.bjid.2023.102759_bib0012","series-title":"Performance Standards for Antimicrobial Susceptibility Testing. M100. Thirty-second edition","year":"2022"},{"key":"10.1016\/j.bjid.2023.102759_bib0013","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1089\/mdr.2015.0220","article-title":"Multidrug-resistant Gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options","volume":"22","author":"Cerceo","year":"2016","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.bjid.2023.102759_bib0014","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12879-015-1123-5","article-title":"Appropriate initial antibiotic therapy in hospitalized patients with Gram-negative infections: systematic review and meta-analysis","volume":"15","author":"Raman","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2023.102759_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015-2017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.bjid.2023.102759_bib0016","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2023.102759_bib0017","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jgar.2021.08.010","article-title":"In vitro activity of ceftazidime\/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018","volume":"27","author":"Kiratisin","year":"2021","journal-title":"J Glob Antimicrob Resist"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867023000193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867023000193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:00:50Z","timestamp":1761408050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867023000193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1413867023000193"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2023.102759","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015\u20122020","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2023.102759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102759"}}